Beth Israel Deaconess Medical Center, Boston, MA
Jonathan L Berry, Jim W Doolin, Garrett Diltz, Tenzin Dechen, Natalia Forbath, Jessica A. Zerillo, Meghan Shea
Background: ASCO’s Quality Oncology Practice Initiative (QOPI) includes process measures on oral chemotherapy education. Whether achievement of these measures has an impact on clinical outcomes and if an intervention to improve these measures can improve outcomes is not yet known. Methods: A retrospective analysis was conducted of patients initiated on oral chemotherapy in an academic medical center site and a community oncology practice between January 2016 and October 2019. The primary aim was to compare the time to emergency department (ED) within 90 days from initiation of oral chemotherapy of patients who met the QOPI process measure through an intervention of pharmacist-driven education with a comparison group of patients who had not received formal education. A secondary aim was to assess for a difference in oral chemotherapy medication persistence. Data were also analyzed by demographics, concurrent parenteral therapy, intent of therapy, and disease group. Results: 285 patients in the education group and 284 patients in the non-education group were analyzed. The education group had a higher proportion of patients with gastrointestinal and gynecologic cancers, and a lower proportion of patients with hematologic malignancies, compared to the non-education group. The education group also had a higher proportion of patients treated at the community practice compared to the non-education group. There was no statistical difference in median time-to-ED, with 49 days (IQR 37-74) in the education group and 59 days (IQR 41-60) in the non-education group (p=0.15). Conclusions: In patients receiving oral chemotherapy, pharmacist-driven education with improvement in QOPI process measures did not result in an improvement in time to ED. One factor contributing to this result may be that only 20% of patients required ED-level care within 90 days of starting oral We continue to collect data regarding medication persistence, which may be a more sensitive outcome measure. At this point, further work is needed to determine if achievement or modification of the QOPI oral chemotherapy process measures results in a clinically significant change in outcome.
Non-Education (N=284) | Education (N=285) | p-value1 | |
---|---|---|---|
ED visit 90 days, n(%) | 58 (20) | 45 (19) | 0.71 |
ED visit 90 days, median (IQR) | 59 (37-74) | 49 (41-60) | 0.15 |
1 Kruskal-Wallis test used for comparing continuous variables.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2016 ASCO Quality Care Symposium
First Author: Anderson Jennifer
2022 ASCO Annual Meeting
First Author: Analia Nguyen
2018 ASCO Quality Care Symposium
First Author: Daniel Aaron Roberts
2018 ASCO Quality Care Symposium
First Author: Emily R. Mackler